Position in LYEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$577,188
-$246,896 QoQ
Shares Held
41,081
0.0% QoQ
Ownership
0.168%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#31
of 87 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ikarian Capital, LLC holds $559,861,982 across 103 Biotechnology names. LYEL ranks #79 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
328,635 | $43,793,900 | |
| 2 | KOD |
Kodiak Sciences Inc.
|
1,059,730 | $41,287,080 | |
| 3 | ALMS |
Alumis Inc.
|
870,548 | $24,497,220 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
72,842 | $24,386,773 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
388,682 | $22,594,084 | |
| 6 | CLDX |
Celldex Therapeutics, Inc.
|
478,500 | $17,804,985 | |
| 7 | RCUS |
Arcus Biosciences, Inc.
|
504,559 | $15,555,553 | |
| 8 | RLMD |
Relmada Therapeutics, Inc.
|
2,148,359 | $14,866,644 |
All Filings in LYEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $577,188 | 41,081 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $824,084 | 41,081 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,264,473 | 41,081 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $711,295 | 43,799 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $387,183 | 43,799 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $471,307 | 876,037 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $816,663 | 1,276,037 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $725,971 | 526,066 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $762,795 | 526,066 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||